Asia Pacific Chronic Cough Market Developments and Forecast by 2027

The chronic cough market in Asia Pacific is expected to grow from US$ 1,136.66 million in 2019 to US$ 2,155.25 million by 2027. This represents a CAGR of 8.4% from 2020 to 2027.

The growth of the market in the region is expected to grow owing to rising incidences of chronic cough, growing product developments to treat chronic cough. Additionally, robust product pipeline, presence of major players and well-developed regulatory policies are projected to drive the Asia Pacific chronic cough market during the forecast period. 

The India has observed fast growth in the chronic cough market within the past few years and is expected to lead the market in Asia Pacific during the forecast period.Chronic cough is defined as a persistent cough that lasts long up to 6-8 weeks. It significantly affects the life of the patients by interrupt sleeping, vomiting, light-headedness, and even rib fractures. Developing countries have to bear the burden of both communicable and noncommunicable diseases simultaneously. The recent Global Burden of Disease (GBD) survey data have shown that both acute and chronic respiratory diseases are prevalent in substantial number in India. Chronic respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD), are of particular importance for having wide variations in morbidity and mortality in various Indian states. There were 28.1 million cases of COPD in India in 1990; this increased to 55.3 million in 2016, showed a September 2018 study published in The Lancet Global Health. India has 18% of the world’s population but 32% of its COPD burden; it further showed Chronic Obstructive Pulmonary Disease (COPD) was the second-highest cause of death in India after heart disease in 2017, killing 1 million (958,000) Indians that year, according to University of Washington’s Global Burden of Disease study, 2018.

India Chronic Cough Market Revenue and Forecast to 2027 (US$ Million)

ASIA PACIFICCHRONIC COUGH – MARKET SEGMENTATION

By Drug Class

• Antihistamines
• Corticosteroids
• Decongestants
• Combination Drug
• Antibiotics
• Acid Blockers
• Other Drug Class

By Route of Administration

• Oral
• Injections
• Nasal
• Other Route of Administration

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Country

• Japan
• China
• India
• South Korea
• Australia

Company Profiles

• Novartis AG
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc.
• Bayer AG
• Mylan N.V.
• Amneal Pharmaceuticals, Inc.
• Cipla Inc.
• Reckitt Benckiser Group plc.
• Sun Pharmaceutical Industries Ltd
• Aurobindo Pharma Ltd

Asia Pacific Chronic Cough Report Scope